Intratio
Loading...
Skip to main content
Model output · Signal date Oct. 16, 2026

Daily Signals

2758 companies scored · Alpha · vs marketSwitch to Total · 30D 90D

Signal date 2026-10-16 Cut-offs from the 2026-10-16 run
Companies scored 2758 IC ≥ 0 · market cap ≥ $100M
Median forecast -0.41% Alpha · 90D
Long–short spread +5.19% Strong Buy minus Strong Sell, mean
Median IC 0.27 Spearman · 90D
Rating changes ▲ 280 ▼ 460 vs the previous run
Cross-section

Distribution of the day's forecasts

90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Signals · All

296 companies

Sorted by market cap ↓ · forecast rankings are part of the paid plans

# Ticker Sector IC Mkt cap Rating 30D 90D Δ
201 NGNENeurogene Inc. Life Sciences 0.03 $465M Unlock rating and forecasts
202 ENTXEntera Bio Ltd. Life Sciences 0.09 $464M Unlock rating and forecasts
203 RGNXREGENXBIO Inc. Life Sciences 0.03 $457M Unlock rating and forecasts
204 ARVNARVINAS, INC. Life Sciences 0.27 $456M Unlock rating and forecasts
205 ALLOAllogene Therapeutics, Inc. Life Sciences 0.04 $453M Unlock rating and forecasts
206 NIKANIKA PHARMACEUTICALS, INC Life Sciences 0.17 $431M Unlock rating and forecasts
207 PRTAPROTHENA CORP PUBLIC LTD CO Life Sciences 0.28 $429M Unlock rating and forecasts
208 AUTLAutolus Therapeutics plc Life Sciences 0.30 $426M Unlock rating and forecasts
209 OVIDOvid Therapeutics Inc. Life Sciences 0.06 $420M Unlock rating and forecasts
210 TLRYTilray Brands, Inc. Life Sciences 0.15 $414M Unlock rating and forecasts
211 ASMBASSEMBLY BIOSCIENCES, INC. Life Sciences 0.06 $409M Unlock rating and forecasts
212 EIKNEikon Therapeutics, Inc. Life Sciences 0.32 $402M Unlock rating and forecasts
213 PROKPROKIDNEY CORP. Life Sciences 0.02 $400M Unlock rating and forecasts
214 CAPRCAPRICOR THERAPEUTICS, INC. Life Sciences 0.45 $390M Unlock rating and forecasts
215 MYGNMYRIAD GENETICS INC Life Sciences 0.39 $381M Unlock rating and forecasts
216 TKNOAlpha Teknova, Inc. Life Sciences 0.37 $380M Unlock rating and forecasts
217 ZURAZura Bio Ltd Life Sciences 0.19 $372M Unlock rating and forecasts
218 EDITEditas Medicine, Inc. Life Sciences 0.20 $361M Unlock rating and forecasts
219 KYTXKyverna Therapeutics, Inc. Life Sciences 0.62 $351M Unlock rating and forecasts
220 INDPIndaptus Therapeutics, Inc. Life Sciences 0.09 $350M Unlock rating and forecasts
221 FENCFENNEC PHARMACEUTICALS INC. Life Sciences 0.37 $350M Unlock rating and forecasts
222 RZLTRezolute, Inc. Life Sciences 0.37 $346M Unlock rating and forecasts
223 CCCCC4 Therapeutics, Inc. Life Sciences 0.31 $340M Unlock rating and forecasts
224 PRLDPrelude Therapeutics Inc Life Sciences 0.04 $334M Unlock rating and forecasts
225 RLMDRELMADA THERAPEUTICS, INC. Life Sciences 0.37 $331M Unlock rating and forecasts
226 VTVTvTv Therapeutics Inc. Life Sciences 0.14 $329M Neutral -0.04% -0.05% ▼ 1
227 EBSEmergent BioSolutions Inc. Life Sciences 0.56 $327M Unlock rating and forecasts
228 ENTAENANTA PHARMACEUTICALS INC Life Sciences 0.52 $323M Unlock rating and forecasts
229 IRDOpus Genetics, Inc. Life Sciences 0.29 $319M Unlock rating and forecasts
230 TTRXTurn Therapeutics Inc. Life Sciences 0.28 $315M Unlock rating and forecasts
231 IKTInhibikase Therapeutics, Inc. Life Sciences 0.07 $300M Unlock rating and forecasts
232 ARCTArcturus Therapeutics Holdings Inc. Life Sciences 0.19 $294M Unlock rating and forecasts
233 USNAUSANA HEALTH SCIENCES INC Life Sciences 0.28 $287M Unlock rating and forecasts
234 ARTVArtiva Biotherapeutics, Inc. Life Sciences 0.25 $286M Unlock rating and forecasts
235 FULCFulcrum Therapeutics, Inc. Life Sciences 0.01 $278M Unlock rating and forecasts
236 CYPHCYPHERPUNK TECHNOLOGIES INC. Life Sciences 0.16 $277M Unlock rating and forecasts
237 SRZNSurrozen, Inc./DE Life Sciences 0.17 $276M Unlock rating and forecasts
238 AGENAGENUS INC Life Sciences 0.59 $272M Unlock rating and forecasts
239 ELTPELITE PHARMACEUTICALS INC /NV/ Life Sciences 0.23 $269M Unlock rating and forecasts
240 OCGNOcugen, Inc. Life Sciences 0.42 $265M Unlock rating and forecasts
241 ACBAURORA CANNABIS INC Life Sciences 0.16 $253M Neutral +0.07% +0.16% ·
242 IPSCCentury Therapeutics, Inc. Life Sciences 0.37 $248M Unlock rating and forecasts
243 CATXPerspective Therapeutics, Inc. Life Sciences 0.10 $248M Unlock rating and forecasts
244 LABSTANDARD BIOTOOLS INC. Life Sciences 0.21 $247M Unlock rating and forecasts
245 PALIPALISADE BIO, INC. Life Sciences 0.13 $246M Unlock rating and forecasts
246 VNDAVanda Pharmaceuticals Inc. Life Sciences 0.28 $244M Unlock rating and forecasts
247 LFCRLIFECORE BIOMEDICAL, INC. \DE\ Life Sciences 0.30 $242M Neutral -0.38% -0.81% ·
248 ABEOABEONA THERAPEUTICS INC. Life Sciences 0.09 $240M Unlock rating and forecasts
249 CABACabaletta Bio, Inc. Life Sciences 0.04 $239M Unlock rating and forecasts
250 AMRNAMARIN CORP PLC\UK Life Sciences 0.05 $238M Unlock rating and forecasts
201–250 of 296 Previous Next
Since the previous run

Rating changes

▲ 280▼ 460
Which companies were upgraded or downgraded is part of the paid plans.
Next step

Unlock the full ranking

Every company's rating, its 30- and 90-day forecasts, the forecast and IC-weighted rankings, the daily rating changes and CSV export.

See plans Create a free account
Methodology

Ratings are relative: the forecasts of the latest complete daily run (2026-10-16) are ranked and cut at the 15th, 35th, 65th and 85th percentiles, so Strong Sell is the bottom 15%, Sell the next 20%, Neutral the middle 30%, Buy the next 20% and Strong Buy the top 15%. Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. IC is the company's Spearman information coefficient between its past forecasts and the realised returns at the selected horizon; IC-weighted ranking multiplies each forecast by its IC (negative IC counts as zero). Δ is the rating move since the company's previous signal, in rating steps. Each company shows its latest signal, including one from a run still in progress; every signal is rated against the cut-offs above. Quantitative research output, not investment advice.